At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 157 enrolled
Drug / intervention
Risankizumab +1 moredrug
Likely dose
Risankizumab 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Risankizumab Using a New Formulation for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Risankizumab and Placebo solution for risankizumab for Psoriasis. Completed, enrolled 157 participants across 43 sites in 2 countries.
Detailed Summary
The primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/mL) administered by prefilled syringe (PFS) for the treatment of adult participants with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 2019
Enrollment StartMay 2019
Primary CompletionFeb 2020
Study CompletionJul 2020
TodayJul 2026
First PostedMar 14, 2019
Enrollment StartMay 13, 2019
Primary CompletionFeb 20, 2020
Study CompletionJul 15, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 7.3 years ago
Interventions
Risankizumabdrug
Risankizumab 150 mg (150 mg/mL) in prefilled syringes, self-administered subcutaneously
Placebo solution for risankizumabdrug
Placebo solution in prefilled syringes, self-administered subcutaneously